课题基金 / 基金详情

TEMOZOLOMIDE & BCNU FOR ANAPLASTIC GLIOMAS

TEMOZOLOMIDE & BCNU FOR ANAPLASTIC GLIOMAS
替莫唑胺
批准号：
6263693
负责人：
HARRY S GREENBERG
金额：
$0.02万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6263693
关键词：
astrocytoma carmustine clinical research combination chemotherapy glioma human subject human therapy evaluation neoplasm /cancer chemotherapy temozolomide

项目摘要

项目成果

HARRY S GREENBERG的其他基金

相似基金

相关文献

中文摘要
翻译
北美脑肿瘤委员会联盟II期多中心试验，联合静脉注射BCNU和口服替莫唑胺治疗恶性星形细胞瘤。这些药物耐药的机制是高水平的O6烷基鸟嘌呤转移酶。BCNU将被用来耗尽这种酶，其理论是替莫唑胺在较低的细胞水平的酶将更有效。将有两个患者组进行研究1。)初治失败后复发的胶质母细胞瘤(手术、放疗和化疗)和2.间变性胶质瘤和混合间变性胶质瘤手术后没有事先放射治疗。
英文摘要
A phase II multicenter North American Brain Tumor Board Consortium trial to treat malignant astrocytomas with the combination of IV BCNU and oral temozolomide. The mechanism of denovo drug-resistance for these drugs is high levels of the enzyme O 6 alkylguanine transferase. BCNU will be used to deplete this enzyme with the theory that temozolomide will be more effective with lower cellular levels of the enzyme. There will be two patient groups studied 1.) recurrent glioblastoma after primary treatment failure (surgery, radiation and chemotherapy) and 2.) anaplastic gliomas and mixed anaplastic gliomas following surgery without prior radiation therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MARIMASTAT IN PATIENTS W/ GLIOBLASTOMA MULTIFORME OF GLIOSARCOMA
MARIMASTAT IN PATIENTS W/ GLIOBLASTOMA MULTIFORME OF GLIOSARCOMA
TEMOZOLOMIDE & BCNU FOR ANAPLASTIC GLIOMAS
MARIMASTAT IN PATIENTS W/ GLIOBLASTOMA MULTIFORME OF GLIOSARCOMA
海外基金